Biologic agents, such as the TNFα antagonists infliximab and adalimumab, have shown promising results in reducing the severity and frequency of recurrences in patients with severe or refractory HS, but are associated with serious adverse events [18-20]. Here, TNF is linked to histiocytic sarcoma.